Major alterations of phosphatidylcholine and lysophosphotidylcholine lipids in the substantia nigra using an early stage model of parkinson’s disease

International Journal of Molecular Sciences

Volumn 16, Issue 8, 2015, Pages 18865-18877

  Farmer, Kyle ^a   Smith, Catherine A ^a   Hayley, Shawn ^a   Smith, Jeffrey ^a  

^a CARLETON UNIVERSITY   (Canada)

Author keywords

6 hydroxydopamine; Early stage model; HPLC ESI MS MS; Lipidomic profile; Parkinson s disease

Indexed keywords

LYSOPHOSPHATIDYLCHOLINE; OXIDOPAMINE; PHOSPHATIDYLCHOLINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOWN REGULATION; ELECTROSPRAY MASS SPECTROMETRY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MALE; NONHUMAN; PARKINSON DISEASE; RAT; SUBSTANTIA NIGRA; UPREGULATION; ANIMAL; DISEASE MODEL; HUMAN; LIPID METABOLISM; METABOLISM; TANDEM MASS SPECTROMETRY;

ANIMALIA; RATTUS;

ANIMALS; DISEASE MODELS, ANIMAL; HUMANS; LIPID METABOLISM; LYSOPHOSPHATIDYLCHOLINES; MALE; PARKINSON DISEASE; PHOSPHATIDYLCHOLINES; RATS; SUBSTANTIA NIGRA; TANDEM MASS SPECTROMETRY;

EID: 84939214960     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms160818865     Document Type: Article

References (57)

1. Bernheimer, H., Birkmayer, W., Hornykiewicz, O., Jellinger, K., Seiteiberger, F. Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. J. Neurol. Sci. 1973, 20, 415-455.
2. Klockgether, T. Parkinson’s disease: Clinical aspects. Cell Tissue Res. 2004, 318, 115-120.
3. Menza, M., Donkin, R., Marin, H. Treatment of depression in Parkinson’s disease. Curr. Psychiatry Rep. 2006, 8, 234-240.
4. Marié, R., Barré, L., Dupuy, B., Viader, F., Defer, G., Baron, J. Relationships between striatal dopamine denervation and frontal executive tests in Parkinson’s disease. Neurosci. Lett. 1999, 260, 77-80.
5. Farmer, K., Rudyk, C., Prowse, N.A., Hayley, S. Hematopoietic cytokines as therapeutic players in early stages Parkinson’s disease. Front. Aging Neurosci. 2015, 7, 126.
6. Perier, C., Bové, J., Wu, D.-C., Dehay, B., Choi, D.-K., Jackson-Lewis, V., Rathke-Hartlieb, S., Bouillet, P., Strasser, A., Schulz, J.B., et al. Two molecular pathways initiate mitochondria-dependent dopaminergic neurodegeneration in experimental Parkinson’s disease. Proc. Natl. Acad. Sci. USA 2007, 104, 8161-8166.
7. Zheng, B., Liao, Z., Locascio, J.J., Lesniak, K.A., Roderick, S.S., Watt, M.L., Eklund, A.C., Zhang-James, Y., Kim, P.D., Hauser, M.A., et al. PGC-1a, a potential therapeutic target for early intervention in Parkinson’s disease. Sci. Transl. Med. 2010, 2, 52-73.
8. Winklhofer, K.F., Haass, C. Mitochondrial dysfunction in Parkinson’s disease. Biochim. Biophys. Acta 2010, 1802, 29-44.
9. Hagenah, J.M., König, I.R., Becker, B., Hilker, R., Kasten, M., Hedrich, K., Pramstaller, P.P., Klein, C., Seidel, G. Substantia nigra hyperechogenicity correlates with clinical status and number of Parkin mutated alleles. J. Neurol. 2007, 254, 1407-1413.
10. Schweitzer, K.J., Brüssel, T., Leitner, P., Krüger, R., Bauer, P., Woitalla, D., Tomiuk, J., Gasser, T., Berg, D. Transcranial ultrasound in different monogenetic subtypes of Parkinson’s disease. J. Neurol. 2007, 254, 613-616.
11. Prasad, K., Winnik, B., Thiruchelvam, M.J., Buckley, B., Mirochnitchenko, O., Richfield, E.K. Prolonged toxicokinetics and toxicodynamics of paraquat in mouse brain. Environ. Health Perspect. 2007, 115, 1448-1453.
12. Goonesinghe, A., Mundy, E.S., Smith, M., Khosravi-Far, R., Martinou, J.-C; Esposti, M.D. Pro-apoptotic Bid induces membrane perturbation by inserting selected lysolipids into the bilayer. Biochem. J. 2005, 357, 109-118.
13. Qin, Z., Zhu, H., Hu, Y. Effects of lysophosphatidylcholine on ß-amyloid-induced neuronal apoptosis. Acta Pharmacol. Sin. 2009, 30, 388-395.
14. Giussani, P., Tringali, C., Riboni, L., Viani, P., Venerando, B. Sphingolipids: Key regulators of apoptosis and pivotal players in cancer drug resistance. Int. J. Mol. Sci. 2014, 15, 4356-4392.
15. Wright, M.M., Howe, A.G., Zaremberg, V. Cell membranes and apoptosis: Role of cardiolipin, phosphatidylcholine, and anticancer lipid. Biochem. Cell Biol. 2004, 26, 18-26.
16. Gulshan, K., Moye-Rowley, W.S. Vacuolar import of phosphatidylcholine requires the ATP-binding cassette transporter Ybt1. Traffic 2011, 12, 1257-1268.
17. Treede, I., Braun, A., Sparla, R., Kühnel, M., Giese, T., Turner, J.R., Anes, E., Kulaksiz, H., Füllekrug, J., Stremmel, W., etal. Anti-inflammatory effects of phosphatidylcholine. J. Biol. Chem. 2007, 252, 27155-27164.
18. Marinova-Mutafchieva, L., Sadeghian, M., Broom, L., Davis, J.B., Medhurst, A.D., Dexter, D.T. Relationship between microglial activation and dopaminergic neuronal loss in the substantia nigra: A time course study in a 6-hydroxydopamine model of Parkinson’s disease. J. Neurochem. 2009, 110, 966-975.
19. Stott, S.R.W., Barker, R.A. Time course of dopamine neuron loss and glial response in the 6-OHDA striatal mouse model of Parkinson’s disease. Eur. J. Neurosci. 2014, 39, 1042-1056.
20. Choudhury, M.E., Sugimoto, K., Kubo, M., Nagai, M., Nomoto, M., Takahashi, H., Yano, H., Tanaka, J. A cytokine mixture of GM-CSF and IL-3 that induces a neuroprotective phenotype of microglia leading to amelioration of (6-OHDA)-induced Parkinsonism of rats. Brain Behav. 2011, 1, 26-43.
21. Hernandes, M.S., Santos, G.D.R., Cafe-Mendes, C.C., Lima, L.S., Scavone, C., Munhoz, C.D., Britto, L.R.G. Microglial cells are involved in the susceptibility of NADPH oxidase knockout mice to 6-hydroxy-dopamine-induced neurodegeneration. PLoS ONE 2013, 5, e75532.
22. Goes, A.T.R., Souza, L.C., Filho, C.B., del Fabbro, L., de Gomes, M.G., Boeira, S.P., Jesse, C.R. Neuroprotective effects of swimming training in a mouse model of Parkinson’s disease induced by 6-hydroxydopamine. Neuroscience 2013, 256, 61-71.
23. Hanrott, K., Gudmunsen, L., O’Neill, M.J., Wonnacott, S. 6-hydroxydopamine-induced apoptosis is mediated via extracellular auto-oxidation and caspase 3-dependent activation of protein kinase Cdelta. J. Biol. Chem. 2006, 251, 5373-5382.
24. Argaud, L., Prigent, A.-F., Chalabreysse, L., Loufouat, J., Lagarde, M., Ovize, M. Ceramide in the antiapoptotic effect of ischemic preconditioning. Am. J. Physiol. Heart Circ. Physiol. 2004, 256, H246-H251.
25. Wright, M.M., McMaster, C.R. Phospholipid synthesis, diacylglycerol compartmentation, and apoptosis. Biol. Res. 2002, 35, 223-229.
26. Hayakawa, T., Chang, M.C.J., Bell, J.M., Seeman, R., Rapoport, S.I., Appel, N.M. Fatty acid incorporation depicts brain activity in a rat model of Parkinson’s disease. Brain Res. 1998, 507, 177-181.
27. Lee, H.-J., Bazinet, R.P., Rapoport, S.I., Bhattacharjee, A.K. Brain arachidonic acid cascade enzymes are up-regulated in a rat model of unilateral parkinson disease. Neurochem. Res. 2010, 35, 613-619.
28. Kim, S.J., Gershov, D., Ma, X., Brot, N., Elkon, K.B. I-PLA2 Activation during apoptosis promotes the exposure of membrane lysophosphatidylcholine leading to binding by natural immunoglobulin M antibodies and complement activation. J. Exp. Med. 2002, 196, 655-665.
29. Jaattela, M., Benedict, M., Tewari, M., Shayman, J.A., Dixit, V.M. Bcl-x and Bcl-2 inhibit TN and Fas-induced apoptosis and activation of phospholipase A1 in breast carcinoma cells. Oncogene 1995, 10, 2297-2305.
30. Ahmad, A.S., Maruyama, T., Narumiya, S., Doré, S. PGE2 EP1 receptor deletion attenuates 6-OHDA-induced Parkinsonism in mice: Old switch, new target. Neurotox. Res. 2013, 23, 260-266.
31. Kreisler, A., Gelé, P., Wiart, J.-F., Lhermitte, M., Destée, A., Bordet, R. Lipid-lowering drugs in the MPTP mouse model of Parkinson’s disease: Fenofibrate has a neuroprotective effect, whereas bezafibrate and HMG-CoA reductase inhibitors do not. Brain Res. 2007, 1135, 77-84.
32. Ravnsjkjaer, K., Frigerio, F., Boegesen, M., Nielsen, T., Maechler, P., Mandrup, S. PPAR-y is a fatty acid sensor that enhances mitochondrial oxidation in insulin-secreting cells and protects against fatty acid-induced dysfunction. J. Lipid Res. 2014, 51, 1370-1379.
33. Kupsch, A., Schmidt, W., Gizatullina, Z., Debska-Vielhaber, G., Voges, J., Striggow, F., Panther, P., Schwegler, H., Heinze, H.-J., Vielhaber, S., et al. 6-Hydroxydopamine impairs mitochondrial function in the rat model of Parkinson’s disease: Respirometric, histological, and behavioral analyses. J. Neural Transm. 2014, 121, 1245-1257.
34. Park, S.Y., Kim, D.Y., Kang, J.-K., Park, G., Choi, Y.-W. Involvement ofactivation of the Nrf2/ARE pathway in protection against 6-OHDA-induced SH-SY5Y cell death by a-iso-cubebenol. Neurotoxicology 2014, 44, 160-180.
35. Khan, M.M., Ahmad, A., Ishrat, T., Khan, M.B., Hoda, M.N., Khuwaja, G., Raza, S.S., Khan, A., Javed, H., Vaibhav, K., et al. Resveratrol attenuates 6-hydroxydopamine-induced oxidative damage and dopamine depletion in rat model of Parkinson’s disease. Brain Res. 2010, 1328, 139-151.
36. Asaithambi, A., Ay, M., Jin, H., Gosh, A., Anantharam, V., Kanthasamy, A., Kanthasamy, A.G. Protein kinase D1 (PKD1) phosphorylation promotes dopaminergic neuronal survival during 6-OHDA-induced oxidative stress. PLoS ONE 2014, 9, e96947.
37. Cunningham, T.J., Yao, L., Lucena, A. Product inhibition of secreted phospholipase A2 may explain lysophosphatidylcholines’ unexpected therapeutic properties. J. Inflamm. 2008, 5, 17.
38. Liu-Wu, Y., Hurt-Camejo, E., Wiklund, O. Lysophosphatidylcholine induces the production of IL-1ß by human monocytes. Atherosclerosis 1998, 137, 351-357.
39. Gonçalves, I., Edsfeldt, A., Ko, N.Y., Grufman, H., Berg, K., Björkbacka, H., Nitulescu, M., Persson, A., Nilsson, M., Prehn, C., et al. Evidence supporting a key role of Lp-PLA2-generated lysophosphatidylcholine in human atherosclerotic plaque inflammation. Arterioscler. Thromb. Vasc. Biol. 2012, 32, 1505-1512.
40. Ryborg, A.K., Deleuran, B., Thestrup-Pedersen, K., Kragballe, K. Lysophosphatidylcholine: A chemoattractant to human T lymphocytes. Arch. Dermatol. Res. 1994, 286, 462-465.
41. McMurray, H.F., Parthasarathy, S., Steinberg, D. Oxidatively modified low density lipoprotein is a chemoattractant for human T lymphocytes. J. Clin. Investig. 1993, 92, 1004-1008.
42. Quinn, M.T., Parthasarathy, S., Steinberg, D. Lysophosphatidylcholine: A chemotactic factor for human monocytes and its potential role in atherogenesis. Proc. Natl. Acad. Sci. USA 1988, 85, 2805-2809.
43. Fabelo, N., Martin, V., Santpere, G., Marin, R., Torrent, L., Ferrer, I., Diaz, M. Severe alterations in lipid composition of frontal cortex lipid rafts from Parkinson’s disease and incidental Parkinson’s disease. Mol. Med. 2011, 17, 1107-1118.
44. Braverman, N.E., Moser, A.B. Functions of plasmalogen lipids in health and disease. Biochim. Biophys. Acta 2012, 1522, 1442-1452.
45. Lohmeyer, M., Bittman, R. Antitumore ether lipids and alkylphosphocholines. Drugs Future 1994, 19, 1021-1037.
46. Dave, P.C., Billington, E., Pan, Y.-L., Straus, S.K. Interaction of alamethicin with ether-linked phospholipid bilayers: Oriented circular dichroism, 31P solid-state NMR, and differential scanning calorimetry studies. Biophys. J. 2005, 59, 2434-2442.
47. Van der Putten, H., Wiederhold, K.H., Probst, A., Barbieri, S., Mistl, C., Danner, S., Kauffmann, S., Hofele, K., Spooren, W.P., Ruegg, M.A., et al. Neuropathology in mice expressing human a-synuclein. J. Neurosci. 2000, 20, 6021-6029.
48. Lotharius, J., Brundin, P. Pathogenesis of Parkinson’s disease: Dopamine, vesicles and a-synuclein. Nat. Rev. Neurosci. 2002, 3, 932-942.
49. Galvin, J.E., Uryu, K., Lee, V.M., Trojanowski, J.Q. Axon pathology in Parkinson ‘ s disease and Lewy body dementia hippocampus contains a-, ß- and y-synuclein. PNAS 1999, 96, 13450-13455.
50. Cheng, H., Ulane, C., Burke, R. Clinical progression in Parkinson’s disease and the neurobiology of axons. Ann. Neurol. 2010, 67, 715-725.
51. Blandini, F., Armentero, M.T., Martignoni, E. The 6-hydroxydopamine model: News from the past. Parkinsonism Relat. Disord. 2008, 14 (Suppl. 2), S124-S129.
52. Sauer, H., Oertel, W.H. Progressive degeneration of nigrostriatal dopamine neurons following intrastriatal terminal lesions with 6-hydroxydopamine: A combined retrograde tracing and immunocytochemical study in the rat. Neuroscience 1994, 59, 401-415.
53. Hernandes, M.S., Cafe-Mendes, C.C., Britto, L.R.G. NADPH oxidase and the degeneration of dopaminergic neurons in parkinsonian mice. Oxid. Med. Cell. Longev. 2013, 2013, 157-857.
54. Segura-Aguilar, J., Kostrzewa, R.M. Neurotoxin mechanisms and processes relevant to Parkinson’s disease: An update. Neurotox. Res. 2015, 27, 328-354.
55. Mielke, M.M., Maetzler, W., Haughey, N.J., Bandaru, V.V.R., Savica, R., Deuschle, C., Gasser, T., Hauser, A.-K., Gräber-Sultan, S., Schleicher, E., et al. Plasma ceramide and glucosylceramide metabolism is altered in sporadic Parkinson’s disease and associated with cognitive impairment: A pilot study. PLoS ONE 2013, 5, e73094.
56. Mapstone, M., Cheema, A.K., Fiandaca, M.S., Zhong, X., Mhyre, T.R., MacArthur, L.H., Hall, W.J., Fisher, S.G., Peterson, D.R., Haley, J.M., et al. Plasma phospholipids identify antecedent memory impairment in older adults. Nat. Med. 2014, 20, 415-418.
57. Paxinos, G., Watson, C. The Rat Brain in Stereotaxic Coordinates; Academic Press: San Diego, CA, USA, 1998; pp. 1-75